Why the study?
Does rapid genomic screening using nanopore sequencing improve diagnostic time compared to standard exome sequencing in adults with thrombotic microangiopathies?
Does rapid genomic screening using nanopore sequencing improve diagnostic time compared to standard exome sequencing in adults with thrombotic microangiopathies?
Rapid genomic screening using nanopore sequencing is feasible and can achieve diagnoses in under 3 days for adult thrombotic microangiopathies.
Answers are grounded in this paper and cite their sources.
May shorten diagnostic timelines in thrombotic microangiopathies; leaves open whether it improves outcomes versus standard exome sequencing.
Using nanopore sequencing, we showed the feasibility and impact of rapid genomic screening for managing thrombotic microangiopathies in 18 prospective cases, achieving diagnoses in <3 days. We compared the results with standard exome sequencing, cost efficiency, and complement blockade initiation.
No takes yet. Share an insight, caveat, or question.
Yousfi et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: